Form 4: Eledon Pharmaceuticals CFO Awarded Stock Options and Restricted Stock Units

Eledon Pharmaceuticals' Chief Financial Officer, Paul Sean Little, was granted stock options and restricted stock units on January 10, 2025, according to a recent SEC filing.

Summary

• Paul Sean Little, the Chief Financial Officer of Eledon Pharmaceuticals, received stock options for 175,000 shares and 75,000 restricted stock units (RSUs) on January 10, 2025.
• The stock options have an exercise price of $4.04 per share and vest over a period of three years, starting January 10, 2026, with full vesting by January 10, 2029.
• The RSUs will vest in two tranches, 50% on January 10, 2027, and the remaining 50% on January 10, 2028.
• Both the stock options and RSUs are subject to accelerated vesting under certain conditions, such as termination of employment or a change of control of the company.
• The filing indicates that these transactions are direct holdings by Mr. Little.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, which is generally positive for aligning management and shareholder interests. There are no negative surprises or concerns.

Positives

• The grant of stock options and RSUs aligns the CFO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.
• The accelerated vesting provisions provide some protection for the CFO in the event of a change of control or termination.

Risks

• The value of the stock options and RSUs is dependent on the future performance of Eledon Pharmaceuticals' stock price.
• The vesting of the options and RSUs is contingent on the CFO's continued employment with the company.

Future Outlook

The document does not contain any specific forward-looking statements about the company's future performance, but the vesting schedule of the options and RSUs suggests a long-term focus.

Industry Context

The granting of stock options and restricted stock units is a common practice in the pharmaceutical industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for executive compensation in the biotech and pharmaceutical industries.
• Vesting schedules of 3-4 years are typical for these types of grants, aligning with long-term value creation.
• Companies like Amgen, Gilead, and Regeneron also use similar equity-based compensation plans for their executives.

Stakeholder Impact

• Shareholders may view the grants positively as they align management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, RSUs, executive compensation, insider trading, Eledon Pharmaceuticals, Paul Sean Little, CFO, vesting